BBS-Bioactive Bone Substitutes
0.319 EUR -8.07%3,878 investors are following this company
BBS-Bioactive Bone Substitutes is a medical technology company. The company designs, develops and constructs biological implants for patients with bone defects and healing problems. The company's solutions are resold under the Artebone brand and are based on tricalcium phosphate (TCP) and bone protein, which stimulates the bone healing process. The company was founded in 2003 and is headquartered in Oulu.
P/E (24e)
-1.84
EV/EBIT (adj.) (24e)
-3.96
P/B (24e)
3.49
Dividend yield-% (24e)
-
Target price
0.40 EUR
Recommendation
Reduce
Updated
6.5.2024
First North Finland
BONEH
Daily low / high price
0.319 / 0.363
EUR
Market cap
6.47M EUR
Turnover
10.07K EUR
Volume
30K
Business risk
Valuation risk
Current
Previous
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Reisjärven Kunta | 13.9 % | 13.9 % |
Finha Capital | 12.1 % | 12.2 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Juliusz Rakowski | 18.12.2023 | 10,000EUR |
Jarmo Halonen | 18.12.2023 | 2,560EUR |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 2.0 | 16.9 |
growth-% | 14,164.3 % | 246.3 % | 755.9 % | |||||
EBITDA | -2.4 | -2.3 | -2.7 | -3.1 | -3.0 | -3.5 | -3.6 | -6.1 |
EBIT (adj.) | -2.6 | -2.6 | -3.0 | -3.4 | -3.2 | -4.0 | -4.2 | -6.8 |
EBIT | -2.6 | -2.6 | -3.0 | -3.4 | -3.2 | -4.0 | -4.2 | -6.8 |
Profit before taxes | -2.7 | -2.8 | -3.1 | -3.5 | -3.3 | -4.3 | -4.4 | -7.0 |
Net income | -2.7 | -2.8 | -3.1 | -3.5 | -3.3 | -4.3 | -4.4 | -7.0 |
EPS (adj.) | -0.42 | -0.40 | -0.32 | -0.18 | -0.17 | -0.22 | -0.23 | -0.36 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -60,775.0 % | -58,500.0 % | -68,150.0 % | -78,738.0 % | -76,239.0 % | -616.5 % | -181.8 % | -36.4 % |
EBIT-% (adj.) | -66,125.0 % | -64,275.0 % | -73,775.0 % | -84,150.0 % | -81,239.0 % | -704.6 % | -210.2 % | -40.0 % |
EBIT-% | -66,125.0 % | -64,275.0 % | -73,775.0 % | -84,150.0 % | -81,239.0 % | -704.6 % | -210.2 % | -40.0 % |
ROE | -59.6 % | -57.0 % | -78.2 % | -74.2 % | -97.3 % | 1,179.5 % | 93.8 % | 67.5 % |
ROI | -24.4 % | -23.1 % | -28.5 % | -31.6 % | -34.1 % | -45.7 % | -43.4 % | -54.0 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 3.72 | 1.71 | 1.00 | 0.49 | 0.32 | 0.32 | 0.32 | 0.32 |
Shares | 6.6 | 7.0 | 9.7 | 19.3 | 19.4 | 19.4 | 19.4 | 19.4 |
Market cap | 24.4 | 11.9 | 9.7 | 9.4 | 6.2 | 6.2 | 6.2 | 6.2 |
Enterprise value | 27.2 | 17.1 | 14.6 | 13.0 | 12.9 | 17.7 | 22.9 | 34.1 |
EV/S | 6,794.3 | 4,270.8 | 3,640.1 | 3,242.8 | 3,216.6 | 31.1 | 11.6 | 2.0 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 4.0 | 3.3 | 2.3 | 1.8 | 3.5 | - | - | - |
P/S | 6,106.6 | 2,984.6 | 2,415.3 | 2,359.1 | 1,544.9 | 10.8 | 3.1 | 0.4 |
Dividend yield | ||||||||
Equity ratio | 48.0 % | 34.6 % | 40.0 % | 48.2 % | 20.9 % | -27.2 % | -68.9 % | -92.4 % |
Gearing ratio | 45.2 % | 141.6 % | 114.7 % | 69.1 % | 378.1 % | -463.6 % | -242.8 % | -201.0 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | |||||||
EBITDA | -1.5 | -1.7 | -3.1 | -1.5 | -1.5 | ||||
EBIT | -1.6 | -1.8 | -3.4 | -1.6 | -1.6 | ||||
Profit before taxes | -1.6 | -1.8 | -3.5 | -1.7 | -1.7 | ||||
Net income | -1.6 | -1.8 | -3.5 | -1.7 | -1.7 |
ShowingAll content types
BBS-Bioactive Bone Substitutes Plc: Notification pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 - Municipality of Reisjärvi
BBS-Bioactive Bone Substitutes Plc: Notification pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 - Finha Capital Oy
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools